Apollo Endosurgery is a holding company. Through its subsidiaries, the company is focused on the design, development and commercialization of medical devices to develop gastrointestinal (GI) therapeutic endoscopy. The company's products are used to provide interventional therapy to patients who suffer from obesity and the co-morbidities associated with obesity, other GI conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon and in the treatment of swallowing disorders as well as to suture in place esophageal stents in order to prevent their migration.

Jones Energy is a holding company. Through its subsidiaries, the company is an oil and gas company engaged in the exploration, development, production and acquisition of oil and natural gas properties in the mid-continent U.S., spanning areas of Texas and Oklahoma. The company's operations are focused on horizontal drilling and completions within two areas in Oklahoma and Texas: the Eastern Anadarko Basin, which targets the Woodford shale and Meramec formations in the Merge area of the STACK/SCOOP plays; and the Western Anadarko Basin, which targets the Cleveland, Granite Wash, Tonkawa and Marmaton formations. As of Dec 31 2017, the company had estimated proved reserves of 104,812,000 barrels of oil equivalent.

LKQ is a holding company. Through its subsidiaries, the company provides alternative vehicle collision replacement products and alternative vehicle mechanical replacement products. The company is also a provider of alternative vehicle replacement and maintenance products in the United Kingdom, Germany, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Poland, Slovakia, Austria, and other European countries. In addition to its wholesale operations, the company operates self service retail facilities across the United States that sell recycled automotive products from end-of-life-vehicles. The company is also a distributor of specialty vehicle aftermarket equipment and accessories.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

REV Group is a holding company. Through its subsidiaries, the company is a designer, manufacturer and distributor of specialty vehicles and related aftermarket parts and services. The company provides customized vehicle solutions for applications including: essential needs (ambulances, fire apparatus, school buses and municipal transit buses), industrial and commercial (terminal trucks, cut-away buses and sweepers) and consumer leisure (recreational vehicles (RVs), and coaches). The company's segments are: Fire and Emergency, which sells fire apparatus equipment and ambulances; Commercial, which produces buses, terminal trucks and sweepers; and Recreation, which provides motorized and towable RV models.

Synovus Financial is a financial services company and a bank holding company. Through its subsidiary bank, Synovus Bank, the company provides commercial banking services and retail banking services. The company's commercial banking services include treasury management, asset management, capital markets services, institutional trust services and commercial, financial and real estate loans. The company's retail banking services include accepting customary types of demand and savings deposits accounts; mortgage, installment and other consumer loans; investment and brokerage services; safe deposit services; automated banking services; automated fund transfers; and Internet-based banking services.

Vical researches and develops biopharmaceutical products, including those based on the company's patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. The company has three active development programs in the area of infectious disease comprised of: HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; antifungal VL-2397 for the treatment of patients with invasive aspergillosis; and an ongoing early stage development program of a treatment for chronic hepatitis B virus infection based on its DNA and lipid-delivery technologies.